2014 Heroes of Chemistry
The American Chemical Society honors seven scientists from Bristol-Myers Squibb whose innovations have led to the discovery of Lomitapide (Juxtapid®), a novel inhibitor of microsomal triglyceride transfer protein (MTP), a treatment for a condition known as familial hypercholesterolemia (FH) which is an inherited, genetic disorder that leads to aggressive and premature cardiovascular disease. The drug was later in-licensed by Aegerion.
In this video, Bristol-Myers Squibb's Scott Biller, John Dickson, Michael Lawrence, David Magnin, Michael Poss, Jeffrey Robl, and Joseph Tino were honored as 2014 ACS Heroes of Chemistry.
The Bristol-Myers Squibb Team
Scott Biller, former Vice President, Pharmaceutical Candidate Optimization at
David Magnin, a former Senior Research
Investigator at Bristol-Myers Squibb
Joseph Tino, a Senior Principal Scientist in Discovery Chemistry at Bristol-Myers Squibb
John Dickson, former Group Leader at Bristol-Myers Squibb
Michael Poss, Director, Millamolecular Chemistry at Bristol-Myers Squibb
Michael Lawrence, a Director in Discovery
Chemistry at Bristol-Myers Squibb
Jeff Robl, Executive Director of the Fibrosis Chemistry department at Bristol-Myers Squibb